卡泊芬净与米卡芬净治疗侵袭性念珠菌病的药物经济学评价

张志琪; 刘书衡; 郭晓龙; 韩宝峰; 崔向丽

doi:10.14009/j.issn.1672-2124.2022.04.017

您当前的位置：

首页 >

文章列表页 >

卡泊芬净与米卡芬净治疗侵袭性念珠菌病的药物经济学评价

用药评价 | 更新时间：2022-10-08

- 卡泊芬净与米卡芬净治疗侵袭性念珠菌病的药物经济学评价
- Pharmacoeconomic Evaluation of Caspofungin and Micafungin in the Treatment of Invasive Candidiasis
- 中国医院用药评价与分析 2022年22卷第4期页码：460-463
- 作者机构：
  
  1. 首都医科大学附属北京友谊医院药学部
  2. 首都医科大学药学院
  3. 中国中医科学院西苑医院药学部
- 作者简介：
- 基金信息：
- DOI：10.14009/j.issn.1672-2124.2022.04.017
  中图分类号： R956;R519.3
- 纸质出版日期：2022，
扫描看全文
张志琪, 刘书衡, 郭晓龙, 等. 卡泊芬净与米卡芬净治疗侵袭性念珠菌病的药物经济学评价[J]. 中国医院用药评价与分析, 2022,22(4):460-463.

ZHANG Zhiqi, LIU Shuheng, GUO Xiaolong, et al. Pharmacoeconomic Evaluation of Caspofungin and Micafungin in the Treatment of Invasive Candidiasis[J]. 2022,22(4):460-463.
张志琪, 刘书衡, 郭晓龙, 等. 卡泊芬净与米卡芬净治疗侵袭性念珠菌病的药物经济学评价[J]. 中国医院用药评价与分析, 2022,22(4):460-463. DOI： 10.14009/j.issn.1672-2124.2022.04.017.

ZHANG Zhiqi, LIU Shuheng, GUO Xiaolong, et al. Pharmacoeconomic Evaluation of Caspofungin and Micafungin in the Treatment of Invasive Candidiasis[J]. 2022,22(4):460-463. DOI： 10.14009/j.issn.1672-2124.2022.04.017.

摘要

目的：比较卡泊芬净和米卡芬净两种抗真菌药治疗侵袭性念珠菌病的有效性和经济性，为临床合理用药提供依据。方法：检索2000年1月至2022年1月PubMed、Embase、the Cochrane Library、中国知网、中国生物医学文献服务系统和万方数据库中相关文献，对卡泊芬净与米卡芬净治疗侵袭性念珠菌病的有效性和安全性进行Meta分析，根据直接医疗成本对两种药物治疗方案进行药物经济学评价，并通过敏感性分析验证结果的稳定性。结果：Meta分析共纳入4篇文献，其中2篇为随机对照研究，2篇为回顾性分析。Meta分析结果显示，卡泊芬净与米卡芬净治疗侵袭性念珠菌病的安全性、有效性相当，差异均无统计学意义(P>0.05)。最小成本法分析结果显示，卡泊芬净方案的成本为17 195.12元，米卡芬净方案的成本为13 601.35元，米卡芬净方案更具有经济学优势。结论：在我国，米卡芬净治疗成人侵袭性念珠菌病较卡泊芬净更具有经济性。

Abstract

OBJECTIVE: To compare the effectiveness and economics of two antifungal drugs

caspofungin and micafungin in the treatment of invasive candidiasis

so as to provide basis for clinical rational drug use. METHODS: PubMed

Embase

the Cochrane Library

CNKI

CBM and Wanfang Data were retrieved to collect the relevant literature

the retrieval time was from Jan. 2000 to Jan. 2022. Efficacy and safety of capofungin and micafengin in the treatment of invasive candidiasis were analyzed by Meta-analysis. Pharmacoeconomic evaluation of two kinds of drug regimens was performed based on direct medical costs. The stability of results was verified by sensitivity analysis. RESULTS: A total of 4 literature were included in the Meta-analysis

including 2 randomized controlled studies and 2 retrospective analyses. Meta-analysis showed that the safety and efficacy of caspofungin and micafungin in the treatment of invasive candidiasis were similar

the difference was not statistically significant（P>0.05）. Results of cost-minimization analysis showed that the cost of capofinnet regimen was 17 195.12 yuan

and the cost of micavennet regimen was 13 601.35 yuan

indicating that micavennet regimen had more economic advantages. CONCLUSIONS: In China

micafungin is more economical than caspofungin in the treatment of invasive candidiasis in adults.

关键词

卡泊芬净米卡芬净侵袭性念珠菌病最小成本法

Keywords

CaspofunginMicafunginInvasive candidiasisCost-minimization analysis

references

查看原文

浏览量

123

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

基于蒙特卡洛模拟探讨卡泊芬净在儿童患者中的给药方案

卡泊芬净预防和治疗侵袭性真菌病的快速卫生技术评估

高效液相色谱法测定人血浆中米卡芬净浓度及其在重症患者中的应用